Podberscek A L, Hsu Y, Serpell J A
Department of Clinical Veterinary Medicine, University of Cambridge.
Vet Rec. 1999 Sep 25;145(13):365-9. doi: 10.1136/vr.145.13.365.
Forty-nine dogs showing signs of separation-related problems were randomly assigned to one of three groups: group A (15 dogs) received a placebo twice daily; group B (17 dogs) received clomipramine at 0.5 to 1.0 mg/kg twice daily; and group C (17 dogs) received clomipramine at 1.0 to 2.0 mg/kg twice daily. All the dogs also received behavioural therapy. Their owners were required to complete questionnaires about their dog's behaviour initially, and one, four and eight weeks after the treatment with clomipramine began. Bipolar ratings scales were used to monitor the frequencies of 'general', 'attachment-related' and 'separation-related' behaviours. Kruskal-Wallis tests and Kendall Rank correlations were used to determine any initial differences between the treatment groups, and the association between the initial scores and behavioural changes after one week of treatment with clomipramine. Extended Mantel-Haenszel statistics were used to evaluate the effects of clomipramine treatment versus the placebo, and Page's test was used to assess the effectiveness of behavioural therapy on its own. There were no significant differences in the demographic characteristics of the owners of the dogs assigned to the three groups. The dogs differed slightly in age between groups, and the dogs in the two clomipramine-treated groups were reported as showing problems at a significantly earlier age than those in the placebo group. Clomipramine treatment had a sustained suppressive effect on the dogs' general activity levels, and a more modest suppressive effect on their attachment-related tendency to want much physical contact with their owners. The typical signs of separation-related behaviour problems were not significantly affected by treatment with clomipramine, but behavioural therapy on its own was highly effective in reducing behavioural problems.
49只表现出与分离相关问题迹象的狗被随机分为三组:A组(15只狗)每天接受两次安慰剂;B组(17只狗)每天接受0.5至1.0毫克/千克的氯米帕明两次;C组(17只狗)每天接受1.0至2.0毫克/千克的氯米帕明两次。所有的狗还接受行为疗法。它们的主人需要在最初以及开始用氯米帕明治疗后的1周、4周和8周完成关于狗的行为的问卷。使用双极评定量表来监测“一般”、“依恋相关”和“分离相关”行为的频率。使用Kruskal-Wallis检验和肯德尔等级相关性来确定治疗组之间的任何初始差异,以及氯米帕明治疗1周后初始分数与行为变化之间的关联。使用扩展的Mantel-Haenszel统计量来评估氯米帕明治疗与安慰剂的效果,使用佩奇检验来评估行为疗法本身的有效性。分配到三组的狗的主人的人口统计学特征没有显著差异。各组狗的年龄略有不同,据报道,两个接受氯米帕明治疗组的狗出现问题的年龄比安慰剂组的狗明显更早。氯米帕明治疗对狗的一般活动水平有持续的抑制作用,对它们与主人有大量身体接触的依恋相关倾向有更适度的抑制作用。与分离相关的行为问题的典型迹象没有受到氯米帕明治疗的显著影响,但行为疗法本身在减少行为问题方面非常有效。